TABLE 2

Antibiotic susceptibility profiles and genotypic characteristics of pretreatment and relapse isolates of M. intracellularea

Isolate by patientTreatment status (mo)MIC (μg/ml)bSusceptibilitycmmpT5 alleleMmpT5 sequencedAtpE sequenced
BDQCLFAMKCLR
1
    1APretreatment0.004≤0.06RR3.1WTWT
    1BOn BDQ (5)0.0080.12RR3.2Gly66→fsWT
    1FPost-BDQ (3)0.004≤0.06RR3.3Arg25→ProAla65→Pro
2
    2APretreatment0.004≤0.06RS7.1WTWT
    2COn BDQ (9)0.03≤0.06RS7.2Val46→GlyWT
    2DPost-BDQ (6)0.030.12RS7.2Val46→GlyWT
3
    3BPretreatment0.0040.12SS5.1Glu177→LysWT
    3FOn BDQ (10)0.0080.25RS5.2Ala23→Pro + Glu177→LysWT
    3GOn BDQ (11)0.0080.5RS5.2Ala23→Pro + Glu177→LysWT
    3HOn BDQ (15)0.008≤0.06RS5.1Glu177→LysWT
4
    4APretreatment0.004≤0.06SS4.1WTWT
    4COn BDQ (4.5)0.0150.25SS4.2Pro104→fsWT
5
    5APretreatment0.004≤0.06RR1.1WTWT
    5COn BDQ (8)0.004≤0.06RR1.2Ala162→ProWT
    5DOn BDQ (15)0.008≤0.06RR1.2Ala162→ProWT
    5EOn BDQ (23)2NDRR1.1WTAla65→Pro
    5FOn BDQ (28)2≤0.06RR1.1WTAla65→Pro
6
    6APretreatment0.0080.12RR5.1Glu177→LysWT
    6BOn BDQ (7)0.0080.25RR5.3Ile19→Ser + Glu177→LysWT
    6CPost-BDQ (4.5)0.0080.25RR5.4Val35→Gly + Glu177→LysWT
    6EPost-BDQ (8.5)0.030.5RR5.1Glu177→LysWT
7
    7APretreatment0.004≤0.06SS7.1WTWT
    7CPost-BDQ (5)0.0150.5SS7.3Pro104→fsWT
    7DPost-BDQ (5)0.030.5SS7.3Pro104→fsWT
    7EPost-BDQ (10)0.030.5SS7.3Pro104→fsWT
  • a For the complete list of pretreatment and relapse isolates, see Table S1.

  • b CLF, clofazimine; ND, not determined.

  • c AMK, amikacin; CLR, clarithromycin; R, resistant; S, susceptible.

  • d WT, wild-type sequence; fs, frameshift mutation.